Sanofi's new drug Lunsekimig injection was approved for clinical trials in China again, intended for the treatment of asthma.
The official website of the China National Medical Products Administration (NMPA) recently announced that the class 1 new drug lunsekimig injection submitted by Sanofi (SNY.US) has obtained a new implied license for clinical trials, intended to be developed for the treatment of high-risk asthma in adults.
Sanofi Treatment of Acute Myeloid Leukemia Granted Orphan Status
MediciNova Shares Are Trading Higher After the Company Announced That It Was Notified by Sanofi That the Sanofi/Novartis Litigation Was Settled.
Novavax Falls After Guidance Cut on Lower Vaccine Sales
Zucara Therapeutics Announces Strategic Investment From Sanofi as Part of US$20 Million Series B Financing
Express News | Medicinova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
